# An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases

> **NCT07174843** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Cell Therapy Group Co.,Ltd** · enrollment: 20 (estimated)

## Conditions studied

- Idiopathic Inflammatory Myopathies(IIM)
- Immune Thrombocytopenia(ITP)
- Systemic Lupus Erythematosus(SLE)

## Interventions

- **BIOLOGICAL:** CD19/CD22/BCMA CAR-T cells(BZE2204)

## Key facts

- **NCT ID:** NCT07174843
- **Lead sponsor:** Shanghai Cell Therapy Group Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2027-08
- **Final completion:** 2027-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174843, "An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07174843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*